Lead party: Eos Capital (Pty) Ltd (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: Fabupharm
Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Ordinary Shares (Equity) · Equity stake: 0.35% · Fund: Eos Capital Allegrow Fund
Lead investor/buyer: Eos Capital (Pty) Ltd · Investors/buyers: Eos Capital (Pty) Ltd
Legal advisers: not identified in the source record.
Source: announced 31 August 2016. Original announcement: eoscapital.com.na.


